Co-Diagnostics, Inc.
For the period ended May 14, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 14, 2026 · Filed May 14, 2026
Use the contents to explore the available documents and sections.
CODX$0.26-3.9%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Recent Developments:
Recent Developments:
| ● | Completed enrollment in the upper respiratory Co-Dx test clinical studies, with more than 1,400 patients enrolled |
|---|---|
| ● | Advanced CoMira Diagnostics’ manufacturing facility in Sudair Industrial City in the Kingdom of Saudi Arabia (“KSA”) through regulatory approval and lease execution, supporting localized manufacturing and expansion across the Middle East and North Africa (“MENA”) |
| ● | Participated in a European trade mission across Switzerland and Germany with the Utah Governor’s Office and World Trade Center Utah, engaging with prospective customers and distributors, including at ESCMID Global 2026 |
| ● | Presented at the Stop TB Partnership Summit in Washington, D.C., showcasing the Company’s Co-Dx PCR tuberculosis (TB) test during a roundtable with U.S. government agencies and global health stakeholders |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.